NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
I'm PortAI, I can summarize articles.
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine Granting of Suitability Petition enables re-filing of Abbreviated New Drug Application ( ANDA ) for NRx's patent-pending preservative-free ketamine product
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments